Market Place
Sourcing Support
MindMed Doses First Patient in Phase 3 Voyage Study for GAD
16 Dec 2024 //
BUSINESSWIRE
MindMed Presents at ACNP 2024 Congress on Neuropsychopharmacology
11 Dec 2024 //
BUSINESSWIRE
MindMed Receives UK Innovation Passport for MM120 Tablet for GAD
05 Dec 2024 //
BUSINESSWIRE
MindMed Appoints Javier Muniz as VP of R&D Strategy
03 Dec 2024 //
BUSINESSWIRE
MindMed Announces New Employee Inducement Grants
02 Dec 2024 //
BUSINESSWIRE
MindMed Appoints Gregg Chief Regulatory & Quality Assurance Officer
18 Nov 2024 //
BUSINESSWIRE
MindMed to Participate in Upcoming Investor Conferences
13 Nov 2024 //
BUSINESSWIRE
MindMed Reports Q3 2024 Financial Results & Business Updates
07 Nov 2024 //
BUSINESSWIRE
MindMed To Host Q3 2024 Results Call And Business Update
24 Oct 2024 //
BUSINESSWIRE
MindMed Announces New Employee Inducement Grants
09 Sep 2024 //
BUSINESSWIRE
MindMed to Participate in September Investor Conferences
04 Sep 2024 //
BUSINESSWIRE
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
13 Aug 2024 //
BUSINESSWIRE
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
09 Aug 2024 //
BUSINESSWIRE
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
09 Aug 2024 //
BUSINESSWIRE
MindMed To Host Q2 2024 Financial Results And Business Update Call
06 Aug 2024 //
BUSINESSWIRE
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
06 Aug 2024 //
BUSINESSWIRE
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
29 Jul 2024 //
BUSINESSWIRE
MindMed Patents MM120 Orally Disintegrating Tablet
17 Jul 2024 //
BUSINESSWIRE
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
28 Jun 2024 //
BUSINESSWIRE
MindMed to Present at H.C. Wainwright Neuro Perspectives Virtual Conference
21 Jun 2024 //
BUSINESSWIRE
MindMed Has Productive End-Of-Phase 2 Meeting With FDA For MM120 In GAD
20 Jun 2024 //
BUSINESSWIRE
Optimi Secures Import Permit For MDMA, Psilocybin From Mind Medicine
29 May 2024 //
GLOBENEWSWIRE
MindMed to Participate in June Conferences
28 May 2024 //
BUSINESSWIRE
MindMed to Participate at May Investor Conferences
09 May 2024 //
BUSINESSWIRE
MindMed Reports First Quarter 2024 Financial Results and Business Updates
08 May 2024 //
BUSINESSWIRE
Progress Toward a New GAD Treatment Paradigm
06 May 2024 //
FIERCE BIOTECH
MindMed To Host Q1 2024 Results Call, Webcast, Business Update
02 May 2024 //
BUSINESSWIRE
MindMed to Present at Upcoming May Medical Conferences
25 Apr 2024 //
BUSINESSWIRE
MindMed to Present at Upcoming April Medical Conferences
02 Apr 2024 //
BUSINESSWIRE
MindMed Announces Voluntary Delisting from Cboe Canada
01 Apr 2024 //
BUSINESSWIRE
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
11 Mar 2024 //
BUSINESSWIRE
MindMed Receives FDA Breakthrough Therapy Designation From Phase 2B of MM120
07 Mar 2024 //
BUSINESSWIRE
MindMed Announces Pricing of Underwritten Offering of Common Shares
07 Mar 2024 //
BUSINESSWIRE
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
01 Mar 2024 //
BUSINESSWIRE
MindMed Reports 2023 Financial Results and Business Updates
28 Feb 2024 //
BUSINESSWIRE
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
MindMed to Participate in the 34th Annual Oppenheimer Conference
07 Feb 2024 //
BUSINESSWIRE
MindMed Announces Business Update and Anticipated Milestones for 2024
08 Jan 2024 //
BUSINESSWIRE
MindMed links LSD to reduced anxiety in phase 2b, plots phase 3
14 Dec 2023 //
FIERCE BIOTECH
MindMed to Host Conference to Discuss Third Quarter 2023 Financial Results
26 Oct 2023 //
BUSINESSWIRE
MindMed Completes Enrollment of Phase 2a Trial of MM-120
24 Oct 2023 //
BUSINESSWIRE
MindMed to Present Data on the Preclinical Activity of MM-402
03 Oct 2023 //
BUSINESSWIRE
MindMed to Participate in the TD Cowen 3rd Annual Neuropsychiatry Summit
14 Sep 2023 //
BUSINESSWIRE
MindMed Completes Enrollment of Phase 2b Trial of MM-120
12 Sep 2023 //
BUSINESSWIRE
MindMed Announces Agreement With Catalent for Its Patented Zydis
03 Aug 2023 //
BUSINESSWIRE
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
03 Aug 2023 //
BUSINESSWIRE
MindMed to Host Conference Discuss Q2 2023 Financial Results
31 Jul 2023 //
BUSINESSWIRE
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry VC
22 Jun 2023 //
BUSINESSWIRE
MindMed Announces Election of All Six Company Nominees at Annual Meeting
21 Jun 2023 //
BUSINESSWIRE
MindMed Provides Overview of Clinical Progress & Corporate Updates
20 Jun 2023 //
BUSINESSWIRE
MindMed to Host Investor Day June 2023
07 Jun 2023 //
BUSINESSWIRE
MindMed to Participate at Upcoming Investor Conferences
01 Jun 2023 //
BUSINESSWIRE
MindMed Publishes Report Validating MindMed’s MM-120 Drug Development Strategy
25 May 2023 //
BUSINESSWIRE
MindMed to Present Data on the Preclinical Activity of MM-402
24 May 2023 //
BUSINESSWIRE
MindMed completes 50% subject enrolment and dosing in GAD therapy trial
18 May 2023 //
CLINICAL TRIALS ARENA
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120
17 May 2023 //
BUSINESSWIRE
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
04 May 2023 //
BUSINESSWIRE
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023
01 May 2023 //
BUSINESSWIRE
MindMed to Participate in May Investor Conferences
26 Apr 2023 //
BUSINESSWIRE
